Back to Search
Start Over
Safety and Short-term Outcomes of High-Dose Erythropoietin in Preterm Infants With Intraventricular Hemorrhage: The EpoRepair Randomized Clinical Trial
- Source :
- Wellmann, Sven; Hagmann, Cornelia F; von Felten, Stefanie; Held, Leonard; Klebermass-Schrehof, Katrin; Truttmann, Anita C; Knöpfli, Claudia; Fauchere, Jean-Claude; Bührer, Christoph; Bucher, Hans Ulrich; Rüegger, Christoph M (2022). Safety and Short-term Outcomes of High-Dose Erythropoietin in Preterm Infants With Intraventricular Hemorrhage: The EpoRepair Randomized Clinical Trial. JAMA Network Open, 5(12):e2244744.
- Publication Year :
- 2022
-
Abstract
- IMPORTANCE Intraventricular hemorrhage (IVH) is a major cause of neonatal morbidity and mortality in preterm infants without a specific medical treatment to date. OBJECTIVE To assess the safety and short-term outcomes of high-dose erythropoietin in preterm infants with IVH. DESIGN, SETTING, AND PARTICIPANTS Between April 1, 2014, and August 3, 2018, a randomized double-blind clinical trial enrolled 121 preterm infants (gestational age <32 weeks or birth weight <1500 g) aged 8 or less days with moderate to severe IVH identified by cerebral ultrasonography from 8 Swiss and Austrian tertiary neonatal units. Statistical analyses were performed between October 1, 2019, and September 12, 2022. INTERVENTIONS Infants received intravenous high-dose erythropoietin (2000 units/kg body weight) or placebo at 4 time points between weeks 1 and 4 of life. MAIN OUTCOMES AND MEASURES Secondary outcomes included (1) mortality and morbidity rates and (2) brain magnetic resonance imaging findings at term-equivalent age (TEA). The primary outcome was the composite intelligence quotient at 5 years of age (not available before 2023). RESULTS Sixty infants (48% male [n = 29]) were randomly assigned to receive erythropoietin, and 61 infants (61% male [n = 37]) were randomly assigned to receive placebo. The median birth weight was 832 g (IQR, 687-990 g) in the erythropoietin group and 870 g (IQR, 680-1110 g) in the placebo group. Median gestation was 26.1 weeks (IQR, 24.8-27.3 weeks) in the erythropoietin group and 27.0 weeks (24.9-28.1 weeks) in the placebo group. The 2 groups had similar baseline characteristics and morbidities. Up to TEA, 10 newborns died (16.7%) in the erythropoietin group, and 5 newborns (8.2%) died in the placebo group (adjusted odds ratio, 2.24 [95% CI, 0.74-7.66]; P = .15). Infants receiving erythropoietin had higher mean hematocrit levels. Conventional magnetic resonance imaging at TEA for 100 infants showed no significant differences in global or regional brain inju
Details
- Database :
- OAIster
- Journal :
- Wellmann, Sven; Hagmann, Cornelia F; von Felten, Stefanie; Held, Leonard; Klebermass-Schrehof, Katrin; Truttmann, Anita C; Knöpfli, Claudia; Fauchere, Jean-Claude; Bührer, Christoph; Bucher, Hans Ulrich; Rüegger, Christoph M (2022). Safety and Short-term Outcomes of High-Dose Erythropoietin in Preterm Infants With Intraventricular Hemorrhage: The EpoRepair Randomized Clinical Trial. JAMA Network Open, 5(12):e2244744.
- Notes :
- application/pdf, info:doi/10.5167/uzh-224283, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1443048520
- Document Type :
- Electronic Resource